Odyssey Health, Inc. (OTCQB: ODYY) announced on November 19, 2025 that it has secured a $25 million financing facility and entered into a nine‑year maintenance service contract for a commercial medical property. The agreements were actually signed on November 13, 2025, but the public disclosure occurred the following day.
The nine‑year contract provides a predictable recurring revenue stream from the maintenance of a commercial medical facility. By locking in long‑term service fees, Odyssey aims to create a steady cash flow that can help offset its ongoing operating losses and address the auditor’s “going concern” opinion. The contract’s revenue is expected to be collected in installments that will also support repayment of a related $2.26 million note tied to the service agreement.
The financing facility is a convertible note with a 10% original issue discount, allowing the company to raise up to $25 million. An initial tranche of $500,000 will be used to advance the BreastCheck® sub‑licensing program, a key revenue‑generating asset. The convertible nature of the note introduces potential dilution for existing shareholders if the note is converted into equity, a risk that management has highlighted in its disclosures.
Odyssey’s financial position remains challenging. For the third quarter of 2025, the company reported a net loss of $251,743, a significant improvement from the $842,341 loss in the same quarter of 2024. For the fiscal year ended July 31, 2025, the net loss was $1.74 million compared with $842,000 in the prior year, and the company’s accumulated deficit rose to $62.75 million. Current liabilities exceed current assets by $6.95 million, underscoring the working‑capital deficit that prompted the auditor’s substantial doubt about the company’s going‑concern status.
President and CEO Michael Redmond emphasized that the new agreements “deliver predictable monthly cash flow and underscore our commitment to building recurring, scalable revenue.” He added that the financing “further positions us to capitalize on growth opportunities across our diversified portfolio and drive long‑term shareholder value.” These comments highlight the company’s focus on stabilizing cash flow while pursuing strategic initiatives such as the BreastCheck® commercialization.
The financing and service contract represent a critical step toward transitioning Odyssey from a development‑stage entity to a cash‑generating operation. However, the company must still manage its net losses, negative cash flow, and potential dilution from the convertible note. Successful deployment of the BreastCheck® sub‑licensing program and the steady income from the maintenance contract will be key to improving the company’s financial health and addressing the auditor’s concerns.
Overall, the announcement signals a strategic effort to strengthen Odyssey’s liquidity and revenue base, but the company’s fragile financial footing and the risk of dilution remain significant considerations for stakeholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.